Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc, Purdue Research FoundationfiledCriticalEndocyte Inc
Publication of AR110942A1publicationCriticalpatent/AR110942A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
Métodos para tratar un paciente con cáncer mediante la administración al paciente de una composición que comprende células T con CAR y una pequeña molécula ligada a una fracción del receptor mediante un conector. Composiciones para su uso en dichos métodos.Methods for treating a cancer patient by administering to the patient a composition comprising T cells with CAR and a small molecule linked to a fraction of the receptor through a linker. Compositions for use in such methods.
ARP180100468A2017-02-282018-02-28
COMPOSITIONS AND METHODS FOR T-CELL THERAPIES WITH CAR
AR110942A1
(en)
Pharmaceutical composition containing a compound derived from imidazo [1,5-a] indole, [1,2,4] triazolo [3,4-a] isoindole, [1,2,3] triazolo [5,1-a] substituted isoindole or 1,4-dihydroindene [1,2-c] and a second therapeutic agent; and its use to treat indoleamine 2,3-dioxygenase-mediated immunosuppression (gone), stimulate t-cell proliferation, inhibit tryptophan degradation in cells expressing gone, to treat a disease associated with gone as an infection or cancer (divisional) of application n ° 2649-2015).
Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors.
Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same
Compounds derived from aminopyrazoloquinazolines, as inhibitors against the phosphorylating activity of the igf-1 receptor located in cell membranes; pharmaceutical preparation that contains them; and its use in the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.